🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Contineum Therapeutics, Inc. Class A Common Stock

Contineum Therapeutics, Inc. Class A Common Stock logo
Market Cap: Medium
Employees: Lowest

PIPE-791

Contineum Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need.

Tags: biopharmaceutical, immunology, inflammation, neuroscience, pipeline

Symbol: CTNM

Recent Price: $14.47

Industry: Biotechnology

CEO: Mr. Carmine N. Stengone MBA, MS

Sector: Healthcare

Employees: 31

Address: 10578 Science Center Drive, San Diego, CA 92121

Phone: (858) 333-5280

Leadership

  • Carmine Stengone, President and Chief Executive Officer
  • Austin Chen, PhD, Senior Vice President, Head of Research
  • Beverly Dixon, Senior Director, Quality Assurance
  • Kristina Haeckl, Sr. Vice President, Regulatory Affairs
  • Daniel Lorrain, PhD, Chief Scientific Officer
  • John Healy, General Counsel & Corporate Secretary
  • Jon Seiders, PhD, Vice President, CMC
  • Jules Lee, Senior Director, Clinical Operations
  • Julie Iwashita, Vice President, Clinical Operations
  • Karin Stebbins, Vice President, Toxicology
  • Michael Mayberry, Vice President, Finance
  • Mike Poon, PhD, Vice President, Biology
  • Peter Slover, Chief Financial Officer
  • Stephen Huhn, MD, Chief Medical Officer & Senior Vice President, Clinical Development
  • Tara Vargas, Senior Director, Project Management
  • Thomas O. Schrader, PhD, Senior Director, Chemistry
  • Varsha Dourado, Vice President, Business Development

Last updated: 2024-12-31